newsfilter
← Latest News
ACCESS Newswire·

FSD Pharma Presents Positive Results on First-In-Human Phase-1 study of Lucid-21-302 (Lucid-MS) at Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) 2024 Forum

TORONTO, ON / ACCESSWIRE / March 5, 2024 / FSD Pharma Inc. , a biopharmaceutical company dedicated to building a portfolio of